ArticleThe journal of headache and pain2022

Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study).

Piero Barbanti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.